Research

Cellular

Tirzepatide is associated with lower mortality compared to both semaglutide and SGLT2 inhibitors.

Tirzepatide may offer a survival advantage for patients with type 2 diabetes.

StrongSupportsmedium confidence
Tirzepatide was associated with lower mortality (HR 0.72, 95% CI 0.58-0.90, p < 0.01; HR 0.29, 95% CI 0.23-0.37, p < 0.01).
Alhena Younis et al. · Diabetes Research and Clinical Practice · 2026

Why this rating

Based on the large cohort study design.

Source

Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study

Alhena Younis et al. · Diabetes Research and Clinical Practice · 2026

DOI 10.1016/j.diabres.2026.113083

cohort · n=14462
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →